Trademark: 86243943
Word
VIVAFOLIN
Status Date
Wednesday, July 12, 2023
Registration Number
5129397
Registration Date
Tuesday, January 24, 2017
Filing Date
Monday, April 7, 2014
Published for Opposition
Tuesday, August 25, 2015
5 Medicines for human purposes, namely, L-5- Methyl tetrahydrofolate for use as a contraceptive; [ Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the respiratory system, gastrointestinal system, endocrine system, cardiovascular system, nervous system, masculoskeletal system, urinary system, integumentary system and reproductive system; Pharmaceutical preparations for treatment of blood disease and disorder; dermatologic pharmaceutical preparations; hormone therapy preparations; Pharmaceutical preparations for the treatments of colds, coughs and influenza; Pharmaceutical preparations for ophthalmic use; Pharmaceutical preparations for treating dandruff, laxatives, analgesics, contraceptives, antiseptics; Pharmaceutical preparations for treatment of hypertension; Pharmaceutical preparations for treatment of obesity; Anti allergic pharmaceutical preparations; Pharmaceutical preparations for treatment of gout; Anti-inflammatory pharmaceuticals; Contraceptive preparations; ] Dietetic foods, namely, folic acid for the treatment of vitamin deficiency; Dietetic substances adapted for medical use, namely, folic acid for the treatment of vitamin deficiency; [ Food for babies; ] Nutritional supplements; Dietary supplement for animals; [ Antibiotics; ] Vitamin preparations; Drugs for medical purposes for the treatment of subacute encephali associated with dementia and vacuolar myelopathy, physiological and pathological vascular and cardiovascular disorders such as premature occlusive arterial diseases, severe vascular diseases in infancy and childhood, progressive arterial stenosis, intermittent claudication, renal vascular hypertension, ischemic cerebrovascular diseases, premature occlusive retinal artery and retinal vein, crebral occlusive arterial diseases, occlusive peripheral arterial diseases, and premature death caused by thromboembolic diseases and/or ischemic heart diseases, autoimmune diseases such as psoriasis, celiac disease, arthritis and inflammatory conditions, megaloblastic anemia caused by folate inficiency, intestinal malabsorption, used as antidote for folic acid antagonists, used for preventing serious toxic effects caused by methotrexate overdose or high-dose therapy, reducing risks of woman miscarriage and/or production of fetuses with neural tube defects, cleft lip and/or palate defects, keeping and/or normalizing homocysteine levels and/or metabolism, changes synthesis of and/or functions and/or variations in DNA and RNA and changes in synthesis of cells and depression
1 Chemical preparations for scientific purposes, other than for medical or veterinary use; Calcium salts; Chemical preparations and raw materials in the nature of L-5- Methyl tetrahydrofolate for use in the manufacture of pharmaceutical, medical and nutritional products; Chemicals for use in industry and science; chemicals for use in the pharmaceutical, nutritional and dietary industries
The mark consists of the wording "VIVAFOLIN".
Color is not claimed as a feature of the mark.
Jul 12, 2023
Notice Of Acceptance Of Sec. 8 - E-Mailed
Jul 12, 2023
Registered - Sec. 8 (6-Yr) Accepted
Jul 12, 2023
Case Assigned To Post Registration Paralegal
Jan 19, 2023
Teas Section 8 Received
Jan 24, 2022
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Jul 15, 2020
Automatic Update Of Assignment Of Ownership
May 9, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
May 9, 2020
Teas Change Of Correspondence Received
May 9, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
May 9, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 9, 2020
Teas Change Of Owner Address Received
Jan 24, 2017
Registered-Principal Register
Dec 21, 2016
Notice Of Acceptance Of Statement Of Use E-Mailed
Dec 20, 2016
Allowed Principal Register - Sou Accepted
Dec 1, 2016
Teas/Email Correspondence Entered
Dec 1, 2016
Correspondence Received In Law Office
Nov 29, 2016
Teas Change Of Correspondence Received
Nov 29, 2016
Teas Response To Office Action Received
Nov 29, 2016
Teas Change Of Correspondence Received
Jul 25, 2016
Notification Of Non-Final Action E-Mailed
Jul 25, 2016
Non-Final Action E-Mailed
Jul 25, 2016
Su - Non-Final Action - Written
Jun 3, 2016
Assigned To Examiner
May 17, 2016
Statement Of Use Processing Complete
Apr 13, 2016
Use Amendment Filed
May 12, 2016
Case Assigned To Intent To Use Paralegal
Apr 13, 2016
Teas Statement Of Use Received
Oct 20, 2015
Noa E-Mailed - Sou Required From Applicant
Aug 25, 2015
Official Gazette Publication Confirmation E-Mailed
Aug 25, 2015
Published For Opposition
Aug 5, 2015
Notification Of Notice Of Publication E-Mailed
Jul 18, 2015
Law Office Publication Review Completed
Jul 18, 2015
Assigned To Lie
Jul 2, 2015
Approved For Pub - Principal Register
Jul 2, 2015
Examiner's Amendment Entered
Jul 2, 2015
Notification Of Examiners Amendment E-Mailed
Jul 2, 2015
Examiners Amendment E-Mailed
Jul 2, 2015
Examiners Amendment -Written
Jun 9, 2015
Teas/Email Correspondence Entered
Jun 8, 2015
Correspondence Received In Law Office
Jun 8, 2015
Teas Request For Reconsideration Received
Jan 5, 2015
Notification Of Final Refusal Emailed
Jan 5, 2015
Final Refusal E-Mailed
Jan 5, 2015
Final Refusal Written
Dec 10, 2014
Teas/Email Correspondence Entered
Dec 10, 2014
Correspondence Received In Law Office
Dec 10, 2014
Teas Response To Office Action Received
Jul 16, 2014
Notification Of Non-Final Action E-Mailed
Jul 16, 2014
Non-Final Action E-Mailed
Jul 16, 2014
Non-Final Action Written
Jul 14, 2014
Assigned To Examiner
Apr 18, 2014
New Application Office Supplied Data Entered
Apr 10, 2014
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
